Sugi Predict

Sugi Predict / Targets / CPT1A

CPT1A

Carnitine O-palmitoyltransferase 1, liver isoform · P50416 · CPT1A on Sugi Atlas →

21,110 patent compounds predicted against CPT1A, 10,956 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL749997 SCHEMBL749997 1.00 20/20
SCHEMBL749999 SCHEMBL749999 1.00 20/20
SCHEMBL750018 SCHEMBL750018 1.00 20/20
SCHEMBL750198 SCHEMBL750198 1.00 20/20
SCHEMBL750306 SCHEMBL750306 1.00 20/20
SCHEMBL750308 SCHEMBL750308 1.00 20/20
SCHEMBL750776 SCHEMBL750776 1.00 20/20
SCHEMBL750825 SCHEMBL750825 1.00 20/20
SCHEMBL750844 SCHEMBL750844 1.00 20/20
SCHEMBL750850 SCHEMBL750850 1.00 20/20
SCHEMBL750876 SCHEMBL750876 1.00 20/20
SCHEMBL750893 SCHEMBL750893 1.00 20/20
SCHEMBL750898 SCHEMBL750898 1.00 20/20
SCHEMBL750901 SCHEMBL750901 1.00 20/20
SCHEMBL750959 SCHEMBL750959 1.00 20/20
SCHEMBL750964 SCHEMBL750964 1.00 20/20
SCHEMBL750967 SCHEMBL750967 1.00 20/20
SCHEMBL751022 SCHEMBL751022 1.00 20/20
SCHEMBL751260 SCHEMBL751260 1.00 20/20
SCHEMBL751311 SCHEMBL751311 1.00 20/20

Clinical trials — most relevant to CPT1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Omega 3 and Ischemic Stroke; Fish Oil as an Option PHASE4UNKNOWN
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects PHASE2COMPLETED
Metabolic Manipulation in Chronic Heart Failure PHASE2COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans PHASE2RECRUITING
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses PHASE2COMPLETED
A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders PHASE1COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates nanCOMPLETED
Metabolic Consequences of CPT-1 Deficiency nanCOMPLETED
Lactate Profile and Fat Oxidation During Exercise nanCOMPLETED
Effect of Carnitine on Uremic Cardiomyopathy nanCOMPLETED
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids nanCOMPLETED
KETO-TUMOR: a Study on Brain Tumors and Central Obesity nanRECRUITING
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism nanNO_LONGER_AVAILABLE
CT Body Composition Enhances Survival Risk Stratification nanCOMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome nanCOMPLETED
The Ketogenic Diet in the Treatment of Behavioral Variant Frontotemporal Dementia nanNOT_YET_RECRUITING
The Ketogenic Diet in the Treatment of Alzheimer's Disease nanCOMPLETED
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study. nanRECRUITING
Hepatic Energy Fluxes in NASH and NAS Patients nanACTIVE_NOT_RECRUITING
In and ex Vivo Mitochondrial Function of the Heart nanCOMPLETED
Longitudinal Study of Mitochondrial Hepatopathies nanSUSPENDED
Effects of Carnitine Supplementation on Liver and Muscle nanCOMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
Impact Of Choline in Patients With NAFLD nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CPT1A binder may also engage these)

ProteinNameSimilarity
Q68Y62 — 1.000 Q68Y62 →
P32198 — 1.000 P32198 →
Q924X2 — 1.000 Q924X2 →
Q63704 — 1.000 Q63704 →
Q8HY46 — 1.000 Q8HY46 →
P97742 — 1.000 P97742 →
Q58DK1 — 1.000 Q58DK1 →
CPT1B Carnitine O-palmitoyltransferase 1, muscle isoform 0.997 landscape →
B2ZGJ1 — 0.995 B2ZGJ1 →
Q90YJ9 — 0.993 Q90YJ9 →
P07668 — 0.993 P07668 →
P11466 — 0.992 P11466 →
Q8BGD5 — 0.991 Q8BGD5 →
O19094 — 0.991 O19094 →
F1LN46 — 0.991 F1LN46 →
P32756 — 0.989 P32756 →
P80235 — 0.988 P80235 →
P13222 — 0.988 P13222 →
Q9DC50 — 0.986 Q9DC50 →
Q03059 — 0.986 Q03059 →
P32738 — 0.986 P32738 →
Q9UKG9 — 0.985 Q9UKG9 →
Q8TCG5 — 0.984 Q8TCG5 →
P32796 — 0.984 P32796 →
Q5U3U3 — 0.983 Q5U3U3 →
P18886 — 0.983 P18886 →
Q7ZXE1 — 0.982 Q7ZXE1 →
CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial 0.982 landscape →
Q6DRC0 — 0.981 Q6DRC0 →
CHAT Choline O-acetyltransferase 0.981 landscape →